Skip to content
10-Q

Quarterly Report

NORTHWEST BIOTHERAPEUTICS INC NWBO

0001104659-26-062661

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 1.64B sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.58B sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.36B sh
Capex Q1 2026 · Mar 31, 2026 $129K
Capex Q1 2026 · Mar 31, 2025 $93K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.51M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.42M
Long Term Debt Q1 2026 · Mar 31, 2026 $59.43M
Long Term Debt Q1 2026 · Dec 31, 2025 $60.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.79M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.04M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$50.54M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$60.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$99.48M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$94.49M
Current Liabilities Q1 2026 · Mar 31, 2026 $82.97M
Current Liabilities Q1 2026 · Dec 31, 2025 $91.7M
Total Liabilities Q1 2026 · Mar 31, 2026 $118.11M
Total Liabilities Q1 2026 · Dec 31, 2025 $128.86M
Current Assets Q1 2026 · Mar 31, 2026 $6.2M
Current Assets Q1 2026 · Dec 31, 2025 $5.52M
Total Assets Q1 2026 · Mar 31, 2026 $80.05M
Total Assets Q1 2026 · Dec 31, 2025 $81.29M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.01
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 −$0.01
Sga Expense Q1 2026 · Mar 31, 2026 $6.54M
Sga Expense Q1 2026 · Mar 31, 2025 $9.34M
Rd Expense Q1 2026 · Mar 31, 2026 $4.86M
Rd Expense Q1 2026 · Mar 31, 2025 $8.35M
Net Income Q1 2026 · Mar 31, 2026 −$3.07M
Net Income Q1 2026 · Mar 31, 2025 −$19.34M
Operating Income Q1 2026 · Mar 31, 2026 −$10.9M
Operating Income Q1 2026 · Mar 31, 2025 −$17.31M
Revenue Q1 2026 · Mar 31, 2026 $494K
Revenue Q1 2026 · Mar 31, 2025 $375K